Data gathered by Meaney et al. [198], who observed a raise in PON1 activity in metformin-treated patients with metabolic syndrome with no significant increase HDL levels, suggest that there is a correlation between PON1 activity and carotidal intima-media thickness reduction. The gene discussed is PON1; the disease is metabolic syndrome.